Relieves inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. ANDA 212460, held by Padagis Israel. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 212460 (Triamcinolone Acetonide), held by Padagis Israel, was first approved by FDA on Feb 5, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Triamcinolone Acetonide Ointment USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 5, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.05% · ointment;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
